Discovery of a Potent and Orally Active Dual GPBAR1/CysLT1R Modulator for the Treatment of Metabolic Fatty Liver Disease

Discovery of a Potent and Orally Active Dual GPBAR1/CysLT1R Modulator for the Treatment of Metabolic Fatty Liver Disease

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are two highly prevalent human diseases caused by excessive fat deposition in the liver. Although multiple approaches have been suggested, NAFLD/NASH remains an unmet clinical need. Here, we report the discovery of a no...

Full description

Bibliographic Details
Main Authors: Stefano Fiorucci, Pasquale Rapacciuolo, Bianca Fiorillo, Rosalinda Roselli, Silvia Marchianò, Cristina Di Giorgio, Martina Bordoni, Rachele Bellini, Chiara Cassiano, Paolo Conflitti, Bruno Catalanotti, Vittorio Limongelli, Valentina Sepe, Michele Biagioli, Angela Zampella
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Pharmacology
Subjects:
cysteinyl-leukotriene-receptor 1
g-protein coupled bile acid receptor 1
nonalcoholic fatty liver disease
nonalcoholic steatohepatitis (NASH)
liver inflammation
REV5901 derivatives
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.858137/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.858137/full

Similar Items